Sha Zhao

Sha Zhao

Auto-generated profile, based on publicly available information

Sha Zhao

Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, PR China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Lung Cancer
Verified
Journal Article
Closed access
SZSha Zhao
Sha Zhao
GGGuanghui Gao
Guanghui Gao
WLWei Li
Wei Li
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
CZCaicun Zhou
Caicun Zhou

1 October 2019 in Lung Cancer
Verified
Journal Article
Closed access
YHYayi He
Yayi He
KJKeyi Jia
Keyi Jia
RDRafal Dziadziuszko
Rafal Dziadziuszko
SZSha Zhao
Sha Zhao
XZXiaoshen Zhang
Xiaoshen Zhang
CZCaicun Zhou
Caicun Zhou

1 February 2019 in Lung Cancer
Verified
Journal Article
Closed access
SZSha Zhao
Sha Zhao
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
TJTao Jiang
Tao Jiang
YJYijun Jia
Yijun Jia
CZCaicun Zhou
Caicun Zhou

17 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GZGuowei Zhang
Guowei Zhang
RCRuirui Cheng
Ruirui Cheng
ZZZengli Zhang
Zengli Zhang
TJTao Jiang
Tao Jiang
SRShengxiang Ren
Shengxiang Ren
JZJun Zhang
Jun Zhang
Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC and BM. 356 NSCLC patients with EGFR mutation and BM were identified. Among them, 91 patients received EGFR-TKIs alone and 105 patients received EGFR-TKIs plus bisphosphonates as first-line therapy. Comparing to TKIs alone, EGFR-TKIs plus bisphosphonates had a statistically significant longer progression-free survival (PFS: 11.6 vs. 9.3 months; HR = 0.68, P = 0.009), while a similar overall survival (OS: 20.5 vs. 19.5 months; HR = 0.95, P = 0.743) in patients with EGFR-mutant NSCLC and BM. The incidence of skeletal-related events in combined group was numerically lower than that in EGFR-TKIs alone group (29.7% vs. 39.4%, P = 0.147). In multivariate analysis, EGFR mutation was found to be a significant independent prognostic factor for OS in NSCLC patients with BM (HR = 0.710, P = 0.021). In conclusion, EGFR mutation was the significant independent prognostic factor for OS and the addition of bisphosphonates to EGFR-TKIs could enhance the antitumor effect of EGFR-TKIs in patients with EGFR-mutant NSCLC and BM.

1 November 2019 in Lung Cancer
Verified
Journal Article
Closed access
YJYijun Jia
Yijun Jia
SZSha Zhao
Sha Zhao
TJTao Jiang
Tao Jiang
XLXuefei Li
Xuefei Li
CZChao Zhao
Chao Zhao
CZCaicun Zhou
Caicun Zhou

6 August 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
PCPeixin Chen
Peixin Chen
LZLishu Zhao
Lishu Zhao
HWHao Wang
Hao Wang
LZLiping Zhang
Liping Zhang
WZWei Zhang
Wei Zhang
CZCaicun Zhou
Caicun Zhou
Background Immunotherapy has revolutionized therapeutic patterns of small cell lung cancer (SCLC). Human leukocyte antigen class II (HLA class II) is related to antitumor immunity. However, the implications of HLA class II in SCLC remain incompletely understood. Materials and methods We investigated the expression patterns of HLA class II on tumor cells and tumor-infiltrating lymphocytes (TILs) by immunohistochemistry staining and its association with clinical parameters, immune markers, and recurrence-free survival (RFS) in 102 patients with stage I–III SCLC with radical surgery. Additionally, an HLA class II-based immune risk model was established by least absolute shrinkage and selection operator regression. With bioinformatics methods, we investigated HLA class II-related enrichment pathways and immune infiltration landscape in SCLC. Results HLA class II on tumor cells and TILs was positively expressed in 9 (8.8%) and 45 (44.1%) patients with SCLC, respectively. HLA class II on TILs was negatively associated with lymph node metastasis and positively correlated with programmed death-ligand 1 (PD-L1) on TILs (p<0.001) and multiple immune markers (CD3, CD4, CD8, FOXP3; p<0.001). Lymph node metastasis (OR 0.314, 95% CI 0.118 to 0.838, p=0.021) and PD-L1 on TILs (OR 3.233, 95% CI 1.051 to 9.95, p=0.041) were independent predictive factors of HLA class II on TILs. HLA class II positivity on TILs prompted a longer RFS (40.2 months, 95% CI 31.7 to 48.7 vs 28.8 months, 95% CI 21.4 to 36.3, p=0.014). HLA class II on TILs, PD-L1 on TILs, CD4, and FOXP3 were enrolled in the immune risk model, which categorized patients into high-risk and low-risk groups and had better power for predicting the recurrence than tumor stage. Pathway enrichment analyses showed that patients with high HLA class II expression demonstrated signatures of transmembrane transportation, channel activity, and neuroactive ligand–receptor interaction. High-risk SCLC patients had a higher proportion of T follicular helper cells (p=0.034) and a lower proportion of activated memory CD4-positive T cells (p=0.040) and resting dendritic cells (p=0.045) versus low-risk patients. Conclusions HLA class II plays a crucial role in tumor immune microenvironment and recurrence prediction. This work demonstrates the prognostic and clinical values of HLA class II in patients with SCLC.